161 related articles for article (PubMed ID: 21718391)
21. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
[TBL] [Abstract][Full Text] [Related]
22. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
25. BU- vs TBI-based conditioning for adult patients with ALL.
Kalaycio M; Bolwell B; Rybicki L; Absi A; Andresen S; Pohlman B; Dean R; Sobecks R; Copelan E
Bone Marrow Transplant; 2011 Nov; 46(11):1413-7. PubMed ID: 21170093
[TBL] [Abstract][Full Text] [Related]
26. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
27. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
28. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].
Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763
[TBL] [Abstract][Full Text] [Related]
29. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kröger N; Krüger W; Wacker-Backhaus G; Hegewisch-Becker S; Stockschläder M; Fuchs N; Rüssmann B; Renges H; Dürken M; Bielack S; de Wit M; Schuch G; Bartels H; Braumann D; Kuse R; Kabisch H; Erttmann R; Zander AR
Bone Marrow Transplant; 1998 Dec; 22(11):1029-33. PubMed ID: 9877263
[TBL] [Abstract][Full Text] [Related]
30. Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients.
Belkacémi Y; Pène F; Touboul E; Rio B; Leblond V; Gorin NC; Laugier A; Gemici C; Housset M; Ozsahin M
Strahlenther Onkol; 1998 Feb; 174(2):92-104. PubMed ID: 9487372
[TBL] [Abstract][Full Text] [Related]
31. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
Zhang GC; Zheng D; Guan XX; Luo SK; Li J; Peng AH; Tong XZ; Lai FZ; Tan EX; Hong WD
Ai Zheng; 2003 Jun; 22(6):620-3. PubMed ID: 12948413
[TBL] [Abstract][Full Text] [Related]
33. Individual physician practice variation in hematopoietic cell transplantation.
Lee SJ; Joffe S; Artz AS; Champlin RE; Davies SM; Jagasia M; Kernan NA; Loberiza FR; Soiffer RJ; Eapen M
J Clin Oncol; 2008 May; 26(13):2162-70. PubMed ID: 18378566
[TBL] [Abstract][Full Text] [Related]
34. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
Nakamae H; Terada Y; Nakane T; Koh H; Nakamae M; Aimoto R; Hirose A; Hayashi Y; Nishimoto M; Inoue E; Yoshimura T; Inoue A; Koh KR; Yamane T; Hino M
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1691-5. PubMed ID: 20841930
[TBL] [Abstract][Full Text] [Related]
35. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
Belkacémi Y; Ozsahin M; Rio B; Laporte JP; Leblond V; Pène F; Laugier A
Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
37. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of cyclic GMP in patients undergoing allogeneic bone marrow transplantation after conditioning with total body irradiation.
Takatsuka H; Wakae T; Mori A; Okada M; Fujimori Y; Okamoto T; Kakishita E; Hara H
Bone Marrow Transplant; 2003 May; 31(10):905-8. PubMed ID: 12748667
[TBL] [Abstract][Full Text] [Related]
39. Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
Wong AM; Allen JC; Goh YT; Linn YC; Loh SM; Diong CP; Chowbay B; Hwang WY
Bone Marrow Transplant; 2012 Feb; 47(2):181-9. PubMed ID: 21478919
[TBL] [Abstract][Full Text] [Related]
40. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
